Adamas Pharmaceuticals, Inc.

Adamas Pharma, LLC

Duke University

Adamas Pharmacueticals, Inc.

Adamas Pharmaceutical, Inc.

Systomics Pharmarceuticals, Inc.

Gregory T Went

Timothy J Fultz

Laurence R Meyerson

Seth Porter

Timothy S Burkoth

Michael Coffee

Gangadhara Ganapati

Natalie McClure

Gayatri Sathyan

Efraim Shek

Ashok Katdare

Kavita Vermani

Sangita Ghosh

David Chernoff

Jack Nguyen

Terry L Burkoth

Mickey S Urdea

Paul Spence

Rowan Chapman

Jonathan S Stamler

Timothy Burkoth

Provided herein are oral pharmaceutical compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, and which have a low level of organic solvent. Provided are also methods of orally administrating a composition comprising amantadine, or a pharmaceutically acceptable salt thereof, to a subject, which has reduced gastrointestinal side effects or sleep disturbances. Further provided are extended release oral compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, that are suitable for once daily administration.

Amantadine compositions, preparations thereof, and methods of use

Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.

Methods of administering amantadine

Method of administering amantadine prior to a sleep period

Methods of using amantadine compositions

Amantadine compositions and preparations thereof

Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin, and pharmaceutically acceptable salts of any of the foregoing, and at least one excipient. At least one of said at least one excipients modifies the release of said drug to provide an extended release form. The pharmaceutical composition have pharmacokinetic properties recited in the claims.

Methods and compositions for the treatment of seizure-related disorders

Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.

Composition and method for treating neurological disease

Growing community of inventors

Mill Valley, CA, United States of America

Gregory T Went